Sernova Biotherapeutics Inc SEOVF
0.08 USD 0.00 (+0.76%)
Nov 4, 2026, 10:55 AM EST
0.0795 Day range 0.085
0.06 52-week range 0.14
- YTD
- -11.67%
- 1 year
- -27.73%
- Market cap
- 30.02M
- EPS (ttm)
- 0.01
- P/E ratio
- 7.95
- YTD return
- -11.67%
- 1-year return
- -27.73%
- Volume
- 20.00K
- Avg volume
- 81.39K
- Open
- 0.085
- Previous close
- 0.0789
- Day's range
- 0.0795 – 0.085
- 52-week range
- 0.06 – 0.14
2Y -0.1005 (-55.83%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2025 | Oct 1, 2024 | 0.00 | -0.01 | — | — |
| Sep 16, 2024 | Jul 1, 2024 | 0.00 | -0.01 | — | — |
| Jun 14, 2024 | Apr 1, 2024 | 0.00 | -0.02 | — | — |
| Mar 18, 2024 | Jan 1, 2024 | 0.00 | -0.02 | — | — |
| Jan 29, 2024 | Oct 1, 2023 | 0.00 | -0.03 | — | — |
| Sep 13, 2023 | Jul 1, 2023 | 0.00 | -0.02 | — | — |
News
Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial 
Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference 
Sernova Biotherapeutics Announces Closing of Recently Approved Financings 
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders 
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing 
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval 
Sernova Biotherapeutics Announces Warrant Amendments 
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang 
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors 
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
Your note
Sign in to keep a note on SEOVF — it syncs with the Stock Master app.